TC Biopharm (Holdings) Plc
TCBPY
$0.19
$0.00-0.11%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 18.12% | 4.56% | -8.38% | -16.90% | -23.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 6,670.00% | -137.73% | -173.46% | -190.74% | -- |
| Total Operating Expenses | -7.20% | -12.31% | -17.00% | -10.37% | -10.83% |
| Operating Income | 7.20% | 3.23% | -2.03% | -13.49% | -16.43% |
| Income Before Tax | -87.68% | -153.34% | -313.08% | -151.15% | -143.10% |
| Income Tax Expenses | 38.02% | 52.88% | 62.63% | 52.54% | 36.13% |
| Earnings from Continuing Operations | -110.63% | -229.85% | -769.76% | -316.97% | -398.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -110.63% | -229.85% | -769.76% | -316.97% | -398.51% |
| EBIT | 7.20% | 3.23% | -2.03% | -13.49% | -16.43% |
| EBITDA | 6.18% | 2.08% | -3.42% | -15.59% | -18.67% |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |